P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)

Authors :: Hui Zhang
F. Tsuji
Naoyuki Nogami
Yuka Fujita
Tao Wang
Terufumi Kato
Noboru Yamamoto
Eric Sbar
Hiroyasu Kaneda
Takashi Takahashi
Seiji Niho
Tony Mok
Kazuhiko Nakagawa
F. Ohyanagi
R. Linke
Source :: Journal of Thoracic Oncology. 12:S2229-S2230
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Dacomitinib
First line treatment
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Gefitinib
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
business
medicine.drug

Full Text Access

Tools